Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints Dr Richard Jones to Rare Disease Unit

He joins the pharma company from Genzyme

Richard Jones - GSK, global commercial leader, rare disease unitGlaxoSmithKline (GSK) has appointed Dr Richard Jones to its Rare Disease Unit in a role that will see him guide commercial strategy across CNS, neuomuscular disorders, rare malignancies and haematology franchises.

He joins the pharma company as global commercial leader (CNS, muscular disorders, rare malignancies and haematology) from Genzyme, where he served as director, EMEA oncology and transplant.

In this position Dr Jones was commercially responsible for the portfolio of assets as well as managing the integration and transition of business development projects.

Prior to Genzyme, he served at Shire in various international commercial and therapy area project lead roles and then worked at the MSI consultancy.

GSK's Rare Disease Unit was set up in February 2010 to leverage its existing capabilities and partnerships and establish further in-licensing opportunities.

In April of that year the pharma company signed a deal $1.5bn potentially worth with Isis Pharmaceuticals to develop new drugs for rare and serious diseases using Isis' antisense drug discovery platform.

Meanwhile, in August 2011 GSK signed a deal with Italian biotech company MolMed to develop a production process for an ex vivo gene therapy for Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency (ADA-SCID), commonly referred to as 'bubble boy disease'.

16th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics